Lys323
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Acetylation Site Page: > Lys323  -  PGK1 (human)

Site Information
CGPESSkkyAEAVTR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 479484
Available spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
immunoassay ( 1 ) , immunoprecipitation ( 1 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 ) , modification-specific antibody ( 1 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:
gastric cancer ( 13 ) , liver cancer ( 1 ) , hepatocellular carcinoma ( 1 ) , lung cancer ( 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 ) , non-small cell lung cancer ( 3 , 4 , 5 , 8 , 9 , 10 , 12 , 14 , 15 ) , non-small cell lung adenocarcinoma ( 2 , 3 , 4 , 5 , 8 , 9 , 12 ) , non-small cell large cell lung carcinoma ( 3 , 9 ) , non-small cell squamous cell lung carcinoma ( 2 , 15 ) , small-cell lung cancer ( 6 , 7 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
ELP3 (human) ( 1 ) , GCN5 (human) ( 1 )
Treatments:
nicotinamide ( 1 ) , siRNA ( 1 ) , trichostatin_A ( 1 )

Downstream Regulation
Effects of modification on PGK1:
enzymatic activity, induced ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 )

Disease / Diagnostics Relevance
Relevant diseases:
liver cancer ( 1 )

References 

1

Hu H, et al. (2017) Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis. Hepatology 65, 515-528
27774669   Curated Info

2

Rikova K (2013) CST Curation Set: 20218; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

3

Rikova K (2013) CST Curation Set: 20219; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

4

Rikova K (2013) CST Curation Set: 20220; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

5

Rikova K (2013) CST Curation Set: 20221; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

6

Rikova K (2013) CST Curation Set: 20213; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

7

Rikova K (2013) CST Curation Set: 20214; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

8

Rikova K (2013) CST Curation Set: 20215; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

9

Rikova K (2013) CST Curation Set: 20216; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

10

Rikova K (2013) CST Curation Set: 20217; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

11

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

12

Rikova K (2013) CST Curation Set: 18854; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

13

Rikova K (2012) CST Curation Set: 16030; Year: 2012; Biosample/Treatment: cell line, MKN45/crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

14

Rikova K (2012) CST Curation Set: 16031; Year: 2012; Biosample/Treatment: cell line, H3255/iressa; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

15

Rikova K (2012) CST Curation Set: 16032; Year: 2012; Biosample/Treatment: cell line, H1703/gleevec; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

16

Choudhary C, et al. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-40
19608861   Curated Info

17

Rikova K (2008) CST Curation Set: 5649; Year: 2008; Biosample/Treatment: cell line, NCI-H2228/inhibitor; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info

18

Farnsworth C (2007) CST Curation Set: 2671; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK
Curated Info

19

Possemato A (2007) CST Curation Set: 2487; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: acK Antibodies Used to Purify Peptides prior to LCMS: Acetylated-Lysine (Ac-K2-100) Rabbit mAb Cat#: 9814, PTMScan(R) Acetyl-Lys Motif (Ac-K) Immunoaffinity Beads Cat#: 1989
Curated Info